Bristol-Myers Squibb (BMY) is set to complete its $7B acquisition of Amylin Pharmaceuticals...

|About: Bristol-Myers Squibb Company (BMY)|By:, SA News Editor

Bristol-Myers Squibb (BMY) is set to complete its $7B acquisition of Amylin Pharmaceuticals (AMLN) after reciving tenders for 85.55% of the latter's shares. Under the deal, AztraZenica (AZN) will now pay $3.4B to Bristol-Myers as part of a collaboration agreement for the development and commercialization of Amylin's products. (PR)